Advanced Medical Solutions Group (LSE:AMS) Interest Expense : £-0.4 Mil (TTM As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Advanced Medical Solutions Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Advanced Medical Solutions Group's interest expense for the six months ended in Dec. 2023 was £ 0.5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.4 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Advanced Medical Solutions Group's Operating Income for the six months ended in Dec. 2023 was £ 8.5 Mil. Advanced Medical Solutions Group's Interest Expense for the six months ended in Dec. 2023 was £ 0.5 Mil. Advanced Medical Solutions Group did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Advanced Medical Solutions Group Interest Expense Historical Data

The historical data trend for Advanced Medical Solutions Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Medical Solutions Group Interest Expense Chart

Advanced Medical Solutions Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.44

-0.40

-0.37

-0.38

Advanced Medical Solutions Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.03	-0.34	-0.03	-0.87	0.48

Advanced Medical Solutions Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.4 Mil.

Advanced Medical Solutions Group (LSE:AMS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Advanced Medical Solutions Group's Interest Expense for the six months ended in Dec. 2023 was £0.5 Mil. Its Operating Income for the six months ended in Dec. 2023 was £8.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was £8.0 Mil.

Advanced Medical Solutions Group's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

The higher the ratio, the stronger the company's financial strength is.

Advanced Medical Solutions Group (LSE:AMS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Medical Solutions Group PLC (LSE:AMS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AMS.GB:UK AQA:Germany

Address

Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT

Website

https://www.admedsol.com

U.K.-based Advanced Medical Solutions was founded in 1991 to design, develop, and manufacture advanced wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The firm derives approximately 60% of total revenue from branded products, with nonbranded contributing 40%.